학술논문
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study
Document Type
Article
Author
Lowenthal, E.D.; Chapman, J.; Ohrenschall, R.; Calabrese, K.; Buisson, S.; Baltrusaitis, K.; Heckman, B.; Kneebone, J.; Milligan, R.; Ward, S.; Yin, D.E.; Adeyeye, A.; Agwu, A.L.; Harrington, C.; Chounta, V.; Huang, J.; Van Solingen-Ristea, R.M.; Crauwels, H.; McCoig, C.C.; Smith-Anderson, C.; Camacho-Gonzalez, A.; D'Angelo, J.; Bearden, A.; Bolton-Moore, C.; Gaur, A.H.; Best, B.M.; Capparelli, E.V.; Hanley, S.; Mathiba, S.R.; Naidoo, M.; Ounchanum, P.; Patel, F.; Paul, M.E.; Townley, E.; Vandermeulen, K.; Whitson, K.; Zabih, S.
Source
In: The Lancet HIV . (The Lancet HIV, April 2024, 11(4):e222-e232)
Subject
Language
English
ISSN
23523018